The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
CTLA-4 blockade synergizes with tumor-derived granulocyte– macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma
Open accessAbstract
Generation of a T cell-mediated antitumor response depends on T cell receptor engagement by major histocompatibility complex/antigen as well as CD28 ligation by B7. CTLA-4 is a second B7 receptor expressed by T cells upon activation that, unlike CD28, appears to deliver an inhibitory signal to T cells. Recently, we and others demonstrated that administration of an anti-CTLA-4 antibody was sufficient to promote regression of several murine tumors. However, certain tumors, such as the SM1 mammary carcinoma, remain refractory to this type of immunotherapy. In the present study, we report that the combination of both CTLA-4 blockade and a vaccine consisting of granulocyte–macrophage colony-stimulating factor-expressing SM1 cells resulted in regression of parental SM1 tumors, despite the ineffectiveness of either treatment alone. This synergistic therapy resulted in long-lasting immunity to SM1 and depended on both CD4+and CD8+T cells. Interestingly, synergy was not observed between CTLA-4 and a B7-expressing SM1 vaccine. Given that granulocyte–macrophage colony-stimulating factor promotes differentiation and activation of dendritic cells as well as enhances cross-priming of T cells to tumor-derived antigens and that SM1 is major histocompatibility complex class II-negative, our findings suggest that CTLA-4 blockade acts at the level of a host-derived antigen-presenting cell. In addition, these results also support the idea that the most effective and synergistic vaccine strategy targets treatments that enhance T cell priming at the level of host-derived antigen-presenting cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sallusto, F., & Lanzavecchia, A. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.179.4.1109 · Cited by 5,129
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citationDranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245
Self-citationCTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells
Caux, C., Dezutter-Dambuyant, C., Schmitt, D., & Banchereau, J. (1992) · Nature · doi:10.1038/360258a0 · Cited by 1,554
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells
Townsend, S. E., & Allison, J. P. (1993) · Science · doi:10.1126/science.7678351 · Cited by 1,136
Self-citationChen, L., Ashe, S., Brady, W. A., Hellström, I., Hellström, K. E., Ledbetter, J. A., McGowan, P., & Linsley, P. S. (1992) · Cell · doi:10.1016/s0092-8674(05)80059-5 · Cited by 1,050
Krummel, M. F., & Allison, J. P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.6.2533 · Cited by 932
Self-citationFearon, E. R., Pardoll, D. M., Itaya, T., Golumbek, P., Levitsky, H. I., Simons, J. W., Karasuyama, H., Vogelstein, B., & Frost, P. (1990) · Cell · doi:10.1016/0092-8674(90)90591-2 · Cited by 916
CTLA-4 ligation blocks CD28-dependent T cell activation.
Walunas, T. L., Bakker, C. Y., & Bluestone, J. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.6.2541 · Cited by 801
Murine interleukin-4 displays potent anti-tumor activity in vivo
Tepper, R. I., Pattengale, P. K., & Leder, P. (1989) · Cell · doi:10.1016/0092-8674(89)90925-2 · Cited by 778
Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4
Golumbek, P. T., Lazenby, A. J., Levitsky, H. I., Jaffee, L. M., Karasuyama, H., Baker, M., & Pardoll, D. M. (1991) · Science · doi:10.1126/science.1948050 · Cited by 719
Gansbacher, B., Zier, K., Daniels, B., Cronin, K., Bannerji, R., & Gilboa, E. (1990) · The Journal of experimental medicine · doi:10.1084/jem.172.4.1217 · Cited by 620
Heufler, C., Koch, F., & Schuler, G. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.2.700 · Cited by 540
Gänsbacher, B., Bannerji, R., Daniels, B. F., Zier, K. S., Cronin, K. A., & Gilboa, E. (1990) · PubMed · Cited by 414
Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer
Kwon, E. D., Hurwitz, A. A., Foster, B. A., Madias, C., Feldhaus, A. L., Greenberg, N. M., Burg, M. B., & Allison, J. P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.15.8099 · Cited by 394
Self-citationCD28-B7 interactions in T-cell activation
Allison, J. P. (1994) · Current Opinion in Immunology · doi:10.1016/0952-7915(94)90120-1 · Cited by 313
Self-citationMorrissey, P. J., Bressler, L., Park, L. S., Alpert, A., & Gillis, S. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.4.1113 · Cited by 282
Watanabe, Y., Kuribayashi, K., Miyatake, S., Nishihara, K., Nakayama, E., Taniyama, T., & Sakata, T. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.23.9456 · Cited by 282
Greenberg, N. M. (1994) · Molecular Endocrinology · doi:10.1210/me.8.2.230 · Cited by 267
Yang, Y., Zou, J.-P., Mu, J., Wijesuriya, R., Ono, S., Walunas, T. L., Bluestone, J. A., Fujiwara, H., & Hamaoka, T. (1997) · PubMed · Cited by 197
In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression.
Levitsky, H. I., Lazenby, A., Hayashi, R. J., & Pardoll, D. M. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.4.1215 · Cited by 189
Levitsky, H. I., Montgomery, J., Ahmadzadeh, M., Staveley-O’Carroll, K., Guarnieri, F., Longo, D. L., & Kwak, L. W. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.10.3858 · Cited by 174
Specificity and longevity of antitumor immune responses induced by B7-transfected tumors.
Townsend, S. E., Su, F. W., Atherton, J. M., & Allison, J. P. (1994) · PubMed · Cited by 134
Self-citationZitvogel, L., Robbins, P. D., Storkus, W. J., Clarke, M. R., Maeurer, M. J., Campbell, R. L., Davis, C., Tahara, H., Schreiber, R. D., & Lotze, M. T. (1996) · European Journal of Immunology · doi:10.1002/eji.1830260624 · Cited by 123
B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
Coughlin, C. M., Wysocka, M., Kurzawa, H., Lee, W. M. F., Trinchieri, G., & Eck, S. L. (1995) · PubMed · Cited by 115
Hurwitz, A. A., Townsend, S. E., Yu, T. F.-Y., Wallin, J. A., & Allison, J. P. (1998) · International Journal of Cancer · Cited by 48
Self-citation
Cited by
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Self-citationA guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Self-citationBagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Metadata
- Authors
- Hurwitz, A. A., Yu, T. F.-Y., Leach, D. R., & Allison, J. P.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1998-08-18
- Volume
- 95
- Issue
- 17
- Pages
- 10067-10071
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2071483270
- Cited by
- 378
- References
- 29
- FWCI
- 4.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.